Who are Pegylated rhG-CSF regimen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MYL-1701P, GP2015, Dutogliptin + Filgrastim, F-627, Drug: Pegylated rhG-CSF: 100µg/kg.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pegylated-rhg-csf-regimen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Pegylated rhG-CSF regimen — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pegylated rhG-CSF regimen (Pegylated rhG-CSF regimen) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: G-CSF receptor agonist. Area: Oncology.

marketed G-CSF receptor agonist G-CSF receptor (CSF3R) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Pegylated rhG-CSF regimen (Pegylated rhG-CSF regimen) — Shandong Provincial Hospital. Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Pegylated rhG-CSF regimen TARGET	Pegylated rhG-CSF regimen	Shandong Provincial Hospital	marketed	G-CSF receptor agonist	G-CSF receptor (CSF3R)
MYL-1701P	MYL-1701P	Mylan Pharmaceuticals Inc	phase 3	G-CSF receptor agonist (pegylated biosimilar)	G-CSF receptor (GCSFR)
GP2015	GP2015	Sandoz	phase 3	G-CSF receptor agonist (biosimilar)	G-CSF receptor (GCSFR)
Dutogliptin + Filgrastim	Dutogliptin + Filgrastim	Recardio, Inc.	phase 3	DPP-4 inhibitor + G-CSF receptor agonist	DPP-4 enzyme; G-CSF receptor (CD114)
F-627	F-627	EVIVE Biotechnology	phase 3	G-CSF receptor agonist	G-CSF receptor (CSF3R)
Drug: Pegylated rhG-CSF: 100µg/kg	Drug: Pegylated rhG-CSF: 100µg/kg	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Pegylated cytokine; G-CSF receptor agonist	G-CSF receptor (CSF3R)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (G-CSF receptor agonist class)

EVIVE Biotechnology · 1 drug in this class
Shandong Provincial Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pegylated rhG-CSF regimen — Competitive Intelligence Brief. https://druglandscape.com/ci/pegylated-rhg-csf-regimen. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab